A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study

• Main Authors: Bancroft, E. K., Page, E. C., Brook, M. N., Thomas, S., Taylor, N., Pope, J., McHugh, J., Jones, A. B., Karlsson, Q., Merson, S., Ong, K. R., Hoffman, J., Huber, C., Maehle, L., Grindedal, E. M., Stormorken, A., Evans, D. G., Rothwell, J., Lalloo, F., Brady, A. F., Bartlett, M., Snape, K., Hanson, H., James, P., McKinley, J., Mascarenhas, L., Syngal, S., Ukaegbu, C., Side, L., Thomas, T., Barwell, J., Teixeira, M. R., Izatt, L., Suri, M., Macrae, F. A., Poplawski, N., Chen-Shtoyerman, R., Ahmed, M., Musgrave, H., Nicolai, N., Greenhalgh, L., Brewer, C., Pachter, N., Spigelman, A. D., Azzabi, A., Helfand, B. T., Halliday, D., Buys, S., Ramon, Y. Cajal T., Donaldson, A., Cooney, K. A., Harris, M., McGrath, J., Davidson, R., Taylor, A., Cooke, P., Myhill, K., Hogben, M., Aaronson, N. K., Ardern-Jones, A., Bangma, C. H., Castro, E., Dearnaley, D., Dias, A., Dudderidge, T., Eccles, D. M., Green, K., Eyfjord, J., Falconer, A., Foster, C. S., Gronberg, H., Hamdy, F. C., Johannsson, O., Khoo, V., Lilja, H., Lindeman, G. J., Lubinski, J., Axcrona, K., Mikropoulos, C., Mitra, A. V., Moynihan, C., Ni Raghallaigh, H., Rennert, G., Collier, R., Offman, J., Kote-Jarai, Z., Eeles, R. A.
• Format: Article in Journal/Newspaper
• Language: English
• Published: Elsevier 2021
• Subjects: Adult; Aged; Biomarkers; Tumor/blood; DNA Mismatch Repair/*genetics; DNA-Binding Proteins/genetics; *Early Detection of Cancer; Germ-Line Mutation; Heterozygote; Humans; Incidence; Male; Middle Aged; MutS Homolog 2 Protein/genetics; Prospective Studies; Prostate-Specific Antigen/blood; Prostatic Neoplasms/*diagnosis/epidemiology/genetics; Arctic
• Online Access: https://hdl.handle.net/11287/622259; https://doi.org/10.1016/s1470-2045(21)00522-2

BACKGROUND: Lynch syndrome is a rare familial cancer syndrome caused by pathogenic variants in the mismatch repair genes MLH1, MSH2, MSH6, or PMS2, that cause predisposition to various cancers, predominantly colorectal and endometrial cancer. Data are emerging that pathogenic variants in mismatch repair genes increase the risk of early-onset aggressive prostate cancer. The IMPACT study is prospectively assessing prostate-specific antigen (PSA) screening in men with germline mismatch repair pathogenic variants. Here, we report the usefulness of PSA screening, prostate cancer incidence, and tumour characteristics after the first screening round in men with and without these germline pathogenic variants. METHODS: The IMPACT study is an international, prospective study. Men aged 40-69 years without a previous prostate cancer diagnosis and with a known germline pathogenic variant in the MLH1, MSH2, or MSH6 gene, and age-matched male controls who tested negative for a familial pathogenic variant in these genes were recruited from 34 genetic and urology clinics in eight countries, and underwent a baseline PSA screening. Men who had a PSA level higher than 3·0 ng/mL were offered a transrectal, ultrasound-guided, prostate biopsy and a histopathological analysis was done. All participants are undergoing a minimum of 5 years' annual screening. The primary endpoint was to determine the incidence, stage, and pathology of screening-detected prostate cancer in carriers of pathogenic variants compared with non-carrier controls. We used Fisher's exact test to compare the number of cases, cancer incidence, and positive predictive values of the PSA cutoff and biopsy between carriers and non-carriers and the differences between disease types (ie, cancer vs no cancer, clinically significant cancer vs no cancer). We assessed screening outcomes and tumour characteristics by pathogenic variant status. Here we present results from the first round of PSA screening in the IMPACT study. This study is registered with ClinicalTrials.gov, ...